General Dynamics Bath Iron Works Awarded Contract for Additional DDG 51 Destroyer
"We are proud to be selected to build this ship for the U.S. Navy and to continue our legacy of contributing to the nation's defense," said Charles F. Krugh, president of Bath Iron Works. "I appreciate the efforts of our team to improve the construction process and build to the plan. We are clawing back schedule so we can deliver more Bath-built ships to our Navy. I would also like to acknowledge and thank our Congressional delegation who added this ship to the Fiscal Year 2025 Defense Appropriations Bill."
Bath Iron Works currently has under construction the Flight IIA Arleigh Burke-class destroyers Harvey C. Barnum Jr. (DDG 124) and Patrick Gallagher (DDG 127) as well as the Flight III configuration destroyers Louis H. Wilson Jr. (DDG 126), William Charette (DDG 130), Quentin Walsh (DDG 132), John E. Kilmer (DDG 134) and Richard G. Lugar (DDG 136).
General Dynamics is a global aerospace and defense company that offers a broad portfolio of products and services in business aviation; ship construction and repair; land combat vehicles, weapons systems and munitions; and technology products and services. General Dynamics employs more than 110,000 people worldwide and generated $47.7 billion in revenue in 2024. More information is available at www.gd.com. More information about General Dynamics Bath Iron Works is available at www.gdbiw.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/general-dynamics-bath-iron-works-awarded-contract-for-additional-ddg-51-destroyer-302519298.html
SOURCE General Dynamics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Brachytherapy Devices Market is Growing at CAGR of 6.7% During 2025 -2031 to Reach US$534.20 Million
NEW YORK, Aug 4, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the Brachytherapy Devices Market is witnessing significant growth due to the rising incidence of cancer worldwide and technological advancements in brachytherapy devices. The Brachytherapy Devices Market value is expected to reach US$534.20 million by 2031 from US$343.57 million in 2024; the market is anticipated to register a CAGR of 6.7% during 2025–2031. The market growth is attributed to the rising incidence of cancer worldwide, the aging population, and the technological advancements in brachytherapy devices. The Brachytherapy Devices Market analysis focuses on advancements such as MRI-compatible applicators and real-time imaging integration that play a vital role in the market growth. The report runs an in-depth analysis of market trends, key players, and future opportunities. Check valuable insights in the Brachytherapy Devices Market report. You can easily get a sample PDF of the report - Overview of Brachytherapy Devices Market Report Findings Rising Incidence of Cancer Worldwide:As per the GLOBOCAN 2020 report, more than 28.4 million new cancer cases are expected to be reported by 2040. An aging population, lack of physical activity, exposure to pollutants in the environment, and alterations in diet lead to increased rates of an internal radiation treatment, is ideal for the treatment of prostate, cervical, breast, and skin cancers. It allows for the radiation to be targeted directly to the tumor and avoid the surrounding healthy tissues, with reduced side effects and improved recovery times. Thus, brachytherapy is becoming increasingly popular among oncologists and cancer remains among the major causes of mortality globally, demand for effective, low-invasive, and affordable treatment procedures is rising. Brachytherapy is meeting this demand, particularly in facilities where it might not be possible to access highly advanced external radiation facilities. Thus, the increasing burden of cancers worldwide propels the market growth. Technological Advancements in Brachytherapy Devices:Advances in the area are improving the accuracy, safety, and effectiveness of treatments, making brachytherapy a progressively appealing choice for cancer technological advancements include the creation of high-dose rate (HDR) and low-dose rate (LDR) machines, which provide more accurate radiation delivery. HDR machines provide for administering higher doses of radiation in shorter times, making treatment faster and more convenient for patients. MRI-compatible applicators and integration of sophisticated imaging are providing better tumor localization and online monitoring of treatment. These advances allow clinicians to target tumors effectively with less exposure to healthy tissues in the proximity. The robot-assisted platforms provide higher accuracy and precision, particularly in challenging anatomical areas. In addition, miniaturization and mobility of brachytherapy equipment are facilitating treatments, especially in developing advances in technology are making brachytherapy more effective and safer but and increasing its uses in treating a broader spectrum of cancers. Consequently, the greater uptake of these machines is contributing to their adoption and setting the limits of cancer treatment even higher. Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and Asia Pacific. Asia Pacific is expected to register the highest CAGR during the forecast period. Stay Updated on Brachytherapy Devices Market Trends: Brachytherapy Devices Market Segmentation Based on product, the Brachytherapy Devices Market is segmented into seeds, brachytherapy afterloaders and applicators, and electronic brachytherapy. The brachytherapy afterloaders segment held the largest market share in 2024. In terms of type, the Brachytherapy Devices Market is categorized into high-dose rate brachytherapy implant and low-dose rate brachytherapy implant. The low-dose rate brachytherapy implant segment dominated the market in 2024. By application, the Brachytherapy Devices Market is segmented into breast cancer, cervical cancer, prostate cancer, lung cancer, and others. The prostate cancer segment dominated the market in 2024. Per end user, the Brachytherapy Devices Market is divided into hospitals and specialty clinics, ambulatory surgical centers, and others. The hospitals and specialty clinics segment dominated the market in 2024. The Brachytherapy Devices Market is segmented into five major regions: North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. Competitive Strategy and Development Key players: Elekta, Varian Medical Systems, Inc., BEBIG Medical, Theragenics Corporation, IsoAid, Siemens Healthineers AG, BXTA, BD, and Eckert and Ziegler are among the major companies operating in the Brachytherapy Devices Market. Trending topics: Advancements in Imaging Technologies, Government Initiatives and Cancer Treatment Programs, Technological Advancements in Brachytherapy Devices, Integration of Artificial Intelligence (AI) and Robotics in brachytherapy, etc. Headlines on Brachytherapy Devices Market Artemis Hospital Announces the Launch of Brachytherapy Services, Expanding Advanced Cancer Care Papua New Guinea Resumes Radiotherapy, Starts Brachytherapy Services with IAEA Support BEBIG Medical Launches SagiNova Brachytherapy System at Father Muller Hospital as a Part of New Healthcare Wing Medanta Patents MAOLO Brachytherapy Device For Advanced Cervical Cancer Treatment Elekta Expands Brachytherapy Portfolio With Acquisition of iCad Inc.'s Xoft Business CivaTech Oncology Receives FDA Approval for CivaSheet Brachytherapy Device Get Premium Copy of Brachytherapy Devices Market Size and Growth Report by 2031 at: Conclusion The growth of the Brachytherapy Devices Market is fueled by the increasing prevalence of cancer, advances in technology, and soaring demand for minimally invasive treatment options. The high-dose rate (HDR) systems, MRI-compatible applicators, and robotic-assisted devices are increasing the accuracy of treatment and speeding up patient recovery. Further, there is a growing demand for affordable and patient-centric therapies, particularly in areas that have poor access to conventional cancer therapy. With increasing uses in prostate, breast, and cervical cancers, the demand for brachytherapy is surging, with better results and accessibility in cancer therapy. The report from The Insight Partners provides several stakeholders—including manufacturers of seeds, brachytherapy afterloaders and applicators, and electronic brachytherapy devices—with valuable insights to navigate this evolving market landscape and unlock new opportunities. Trending Related Reports: Brachytherapy After Loaders Market Strategies, Top Players, Growth Opportunities, Analysis and Forecast by 2031 Cancer Therapy Market Scope, Share, and Size by 2031 Pancreatic Cancer Therapy Market SWOT Analysis by 2031 Lung Cancer Therapy Market Research Report by 2030 Cancer Biopsies Market Trends, Share, and Growth – 2031 Cervical Cancer Diagnostics and Therapeutics Market Size 2031 Kidney Cancer Therapeutics And Diagnostics Market Size 2031 Cancer Biopsies Market Trends, Share, and Growth - 2031 Thyroid Cancer Diagnostics Market Growth and Share by 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact Us:If you have any queries about this report or if you would like further information, please get in touch with us:Contact Person: Ankit MathurE-mail: +1-646-491-9876 Logo: View original content: SOURCE The Insight Partners Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
8 minutes ago
- Yahoo
Michigan State football loses recruiting staff member to Nevada
A familiar face in the recruiting department has departed Michigan State for a new position in the college football world. Austin D'Armond has left his role with Michigan State to become the Director of Player Personnel & Recruiting Strategy at Nevada. During his time at MSU, he held the role of Director of Player Personnel/Defense working on the Spartans recruiting efforts on the defensive side of the ball. Prior to joining Jonathan Smith and company in East Lansing, D'Armond was a member of Smith's staff in Corvallis at Oregon State for two seasons in a similar recruiting role. Getting an undergraduate and graduate degrees from Texas, D'Armond spent two years as a recruiting intern, and upon graduating, he became a player personnel graduate assistant for the Longhorns. Michigan State has already filled some of the void he left, adding Michael Morales from Texas to the staff, and there is an expectation that the Spartans could be making one or two more hires in it's recruiting department, that is led by Director of Recruiting and Player Relations, Michael Doctor. Contact/Follow us @The SpartansWire on X (formerly Twitter) and like our page on Facebook to follow ongoing coverage of Michigan State news, notes and opinion. You can also follow Cory Linsner on X @Cory_Linsner This article originally appeared on Spartans Wire: Michigan State football loses member of recruiting staff
Yahoo
8 minutes ago
- Yahoo
Fmr. Commerce Sec. Wilbur Ross explains Trump's BLS suspicions
Tariffs on countries like Japan and Switzerland remain in place as Trump pushes to improve the US trade balance. Wilbur Ross, former US Commerce Secretary, joins Opening Bid to discuss trade policy and prospects for a China deal. To watch more expert insights and analysis on the latest market action, check out more Opening Bid. So what's next on the trade deal front? Want to welcome back onto Opening Bid, longtime investor Wilbur Ross. Mr. Ross served as the U.S. Commerce Secretary in President Trump's first term and has had a close relationship with the president for decades. Mr. Secretary, always nice to get some time with you. Appreciate you coming on here. Um, before we get into the topic of trade, I'm sure you've seen what's been going on, uh, with the president, uh, dismissing or firing the BLS commissioner. You know, you're a longtime investor. Do you still believe that the economic data coming out of the government? Well, I think what is a little bit suspicious about the most recent BLS data is it came out shortly after the Fed FOMC meeting where Trump was hoping to get rates reduced. And clearly, if the two big revisions had come out before the meeting, it would have been more likely that the FOMC would cut rates. And that's the second time that that sort of suspicious behavior occurred. Remember, just before the presidential election, they also had two months of very good, uh, labor results, and then a day or two after the election, they made a massive correction in both months. Again, had that been out before the election, it would have been helpful to Trump. So, I can understand why he would be suspicious at least of the timing as to whether the underlying data themselves are correct. I I would really have no way to know. But it is a little spooky that there were two recent events, big numbers, big changes, uh, that could have helped Trump, had they been more timely. Do you believe, uh, Mr. Secretary, uh, before we get into the trade, I, like the president, noted on Friday after the numbers were hit, that this data is rigged, not only the jobs data, but perhaps other data that the government provides? Well, I think that's just speculation. Um, I certainly never tried to influence the data that came out of the Bureau of Economic Analysis, which is part of Department of Commerce. We never had any problems like that during my term. But we also never had the kinds of events that I just described to you that naturally make one a little suspicious. Mr. Secretary, on the on the trade front, um, since we last talked, tariffs have stayed in place for many countries. I mentioned Japan at 15%, Switzerland now at 39%. Are tariffs the new normal for the duration of the president's, uh, second term here in your view? Or is there an opportunity to take these 15% tariff rates that that Japan is now paying and negotiate them down further? Well, I think the president has made clear that if there are further reductions by other countries, that he would take that into account. So, his target is really improving our balance of trade. That's one of his major objectives. And that can either be done by holding back the trade of foreign countries through tariffs or by everybody cutting it together. So, I think trade policy will continue to be a centerpiece of his administration, but that doesn't mean everything will be increasing. What gets, uh, a deal with China over the finish line? Well, China, as you know, is going to be having their big party Congress very, very shortly. And, as you may know, I've felt for some time that it was unlikely that they would make a radical change in policy before the Party Congress. They don't normally do that. And, uh, I think that Congress is either this week or next week. So, we should know pretty soon if anything different will come out of that. But certainly, the news that was out today about the critical materials, uh, being still restricted, that was not very encouraging. Uh, Mr. Secretary, the fact that China has not solidified a deal with the U.S. on trade, is it likely then that its tariff rate will be higher than what we saw, uh, from the likes of Japan and, of course, the European Union? Well, it's up pretty high right now. And it's, um, I I don't know whether he would make it even higher, but, you know, once you get to about 30 or so percent on the tariffs, it doesn't make too much difference if you go beyond because 30 odd percent is very, very hard for a country to absorb. And as a result, 30 or so percent is the demarcation between are you going to be doing trade with them or not. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
